Adagene logo

Adagene(NASDAQ) ADAG

Market Cap$191.36MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-91%
5 Year-80%
1 Year+47%
1 Month-23%
Premium Feature
Moneyball Superscore
61/100
$2.85
+0.00%
+0.00Today
Adagene last closing stock price
MetricPriceDate
Last closeUSD 2.852026-10-02
Adagene stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.73%USD 2.932026-09-25
1 month-22.76%USD 3.692026-09-02
3 month-36.24%USD 4.472026-07-02
Year to date+50.79%USD 1.892025-12-31
1 year+46.91%USD 1.942025-10-02
3 year+88.74%USD 1.512023-10-03
5 year-80%USD 14.252021-10-01
Since inception-90.5%USD 29.992021-02-09

Adagene Financials at a Glance

Market Cap

$191.36MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$9.42M

Net Income (TTM)

-$58.99M

EPS (TTM)

-$0.38

P/E Ratio

-7.55

Dividend

$0.00

Beta (Volatility)

0.36 (Low)

Price

$2.85

Volume

162,526.225

Open

$2.84

Previous Close

$2.85

Daily Range

$2.67 - $2.86

52-Week Range

$1.30 - $4.85

Estimated Earnings Date

Mar 31, 2027

ADAG News

No articles available.

ADAG: Motley Fool Moneyball Superscore

61

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Adagene

Adagene Inc. is a clinical-stage biopharmaceutical company focused on developing monoclonal antibody-based therapeutics to treat various cancers. The company is advancing several investigational assets through human trials, showcasing a robust pipeline aimed at addressing significant unmet medical needs.

Products and Services
  • ADG106: Anti-CD137 monoclonal antibody in Phase 1b/2 trials
  • ADG126 and ADG116: Anti-CTLA-4 monoclonal antibodies in Phase 1 studies
  • ADG104: Anti-PD-L1 monoclonal antibody in Phase 2 development
Growth Outlook
  • Strong pipeline with multiple candidates in clinical trials
  • Recent cash position of $127.9 million supports ongoing research
  • Potential for partnerships to enhance development capabilities
Financial Highlights
  • Q2 2026 revenue of $1.62 million, showing growth from previous quarters
  • Cash and short-term investments of $127.9 million as of June 2026
  • Current ratio of 5.02 indicates strong liquidity position
Adagene Inc. operates in the biotechnology sector, primarily focusing on innovative cancer therapies. The company has made significant strides in its clinical pipeline, with several promising candidates undergoing various stages of development. The recent financial data indicates a solid cash position, which is crucial for funding ongoing research and development efforts. The current ratio suggests that the company is well-positioned to meet its short-term obligations, providing a level of financial stability. With a focus on advancing its therapeutic candidates and potential collaborations, Adagene Inc. presents an intriguing opportunity for investors interested in the biotechnology space.
AI Generated • Sep 23, 2026

Industry

Biotechnology

Sector

Health Care

Employees

128

CEO

Peizhi Luo, PhD

Website

www.adagene.com

Headquarters

Suzhou, JS 215123, CN

ADAG Financials

Key Financial Metrics (TTM)

Gross Margin

94.22%

Operating Margin

-240.31%

Net Income Margin

-220.66%

Return on Equity

-29.09%

Return on Capital

-51.52%

Return on Assets

-15.39%

Earnings Yield

-13.25%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$191.36MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

67.14M

Volume

162.53K

Avg. Volume

260.97K

Financials (TTM)

Gross Profit

$7.65M

Operating Income

-$64.91M

EBITDA

-$59.98M

Operating Cash Flow

-$53.47M

Capital Expenditure

-$200.96K

Free Cash Flow

-$53.67M

Cash & ST Invst.

$127.91M

Total Debt

$6.09M

Adagene Performance Analysis

Adagene annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 9,281,682-8.9%
20232023-12-31USD 18,095,74795.0%
20242024-12-31USD 103,256-99.4%
20252025-12-31USD 7,691,1907348.7%
Adagene sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31N/A
Q22025-06-30N/A
Q42025-12-31N/A
Q22026-06-30N/A
Adagene annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.840.7%
20232023-12-31USD -0.43-76.6%
20242024-12-31USD -0.7471.8%
20252025-12-31USD -0.37-49.6%
Adagene sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31N/A
Q22025-06-30N/A
Q42025-12-31N/A
Q22026-06-30N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$1.62M

N/A

Gross Profit

$1.37M

+368.5%

Gross Margin

84.20%

N/A

Market Cap

$191.36MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.49M

N/A

Employees

128

N/A

Net Income

-$16.41M

-93.0%

EBITDA

-$16.36M

-82.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$127.91M

+33.7%

Total Debt

$6.09M

-70.7%

Accounts Receivable

$153.03K

+387.1%

Inventory

$0.00

N/A

Long Term Debt

$1.21M

-74.1%

Short Term Debt

$4.88M

-69.7%

Return on Assets

-15.39%

N/A

Return on Invested Capital

-20.88%

N/A

Free Cash Flow

-$14.91M

-122.7%

Operating Cash Flow

-$14.75M

-120.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NRXPNRx Pharmaceuticals, Inc.
$2.82-2.88%
NTRBNutriband Inc.
$7.46+2.40%
GANXGain Therapeutics, Inc.
$1.73+0.88%
FBIOFortress Biotech, Inc.
$2.13+4.68%

Trending Stocks

Symbol / CompanyPricePrice Chg
EWZiShares - iShares Msci Brazil ETF
$43.25+13.25%
NUNu Holdings
$15.16+12.88%
ITUBItaú Unibanco
$9.97+16.01%
SPCXSpace Exploration Technologies
$168.38+5.93%

Questions About ADAG

What is the current price of Adagene?

Adagene is trading at $2.85 per share.

What is the 52-week range for Adagene?

Over the past 52 weeks, Adagene has traded between $1.30 and $4.85.

How much debt does Adagene have?

As of the most recent reporting period, Adagene reported total debt of $6.26M.

How much cash does Adagene have on hand?

Adagene reported $74.52M in cash and cash equivalents in its most recent financial results.

What is Adagene’s dividend yield?

Adagene does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services